Gerald Cochran1, Craig Field2, Kenneth Lawson3. 1. School of Social Work, University of Pittsburgh, Pittsburgh, PA, USA gcochran@pitt.edu. 2. Health Behavior Research and Training Institute, The University of Texas at Austin, Austin, TX, USA. 3. College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Abstract
BACKGROUND: Prescription opioid (PO) abuse has reached epidemic proportions in the United States, and pharmacies are locations from which these medications are often diverted. This study identifies factors associated with pharmacists who currently screen and discuss PO misuse with patients. METHODS: A secondary data analysis of a cross-sectional Web-based survey that was sent to pharmacists was conducted. The survey contained items that assessed whether pharmacists currently screened and discussed PO misuse with patients along with pharmacists' attitudes and beliefs toward providing brief interventions. Multivariable models were developed which identified factors associated with pharmacists' currently screening and discussing misuse. RESULTS: Chain setting pharmacists (odds ratio [OR] = 6.16, 95% confidence interval [CI] = 1.16-32.72) and pharmacists interested in being directly involved in PO screening and brief intervention research projects (OR = 2.06, 95% CI = 1.35-3.15) were most likely to report current screening. Pharmacists who reported currently screening for misuse (OR = 4.27, 95% CI = 2.83-6.45) and who reported wanting to help patients who misuse POs (OR = 3.03, 95% CI = 1.50-6.15) were most likely to currently discuss abuse. CONCLUSIONS: Investigators implementing pharmacy-based screening and brief intervention studies for POs should take into account practice location and pharmacists' interest in addressing PO issues.
BACKGROUND: Prescription opioid (PO) abuse has reached epidemic proportions in the United States, and pharmacies are locations from which these medications are often diverted. This study identifies factors associated with pharmacists who currently screen and discuss PO misuse with patients. METHODS: A secondary data analysis of a cross-sectional Web-based survey that was sent to pharmacists was conducted. The survey contained items that assessed whether pharmacists currently screened and discussed PO misuse with patients along with pharmacists' attitudes and beliefs toward providing brief interventions. Multivariable models were developed which identified factors associated with pharmacists' currently screening and discussing misuse. RESULTS: Chain setting pharmacists (odds ratio [OR] = 6.16, 95% confidence interval [CI] = 1.16-32.72) and pharmacists interested in being directly involved in PO screening and brief intervention research projects (OR = 2.06, 95% CI = 1.35-3.15) were most likely to report current screening. Pharmacists who reported currently screening for misuse (OR = 4.27, 95% CI = 2.83-6.45) and who reported wanting to help patients who misuse POs (OR = 3.03, 95% CI = 1.50-6.15) were most likely to currently discuss abuse. CONCLUSIONS: Investigators implementing pharmacy-based screening and brief intervention studies for POs should take into account practice location and pharmacists' interest in addressing PO issues.
Authors: Gerald Cochran; Jennifer L Bacci; Thomas Ylioja; Valerie Hruschak; Sharon Miller; Amy L Seybert; Ralph Tarter Journal: J Am Pharm Assoc (2003) Date: 2016-03-24
Authors: Aaron Salwan; Nicholas E Hagemeier; Fred Tudiver; KariLynn Dowling-McClay; Kelly N Foster; Jessie Arnold; Arsham Alamian; Robert P Pack Journal: J Am Pharm Assoc (2003) Date: 2020-07-12
Authors: Nicholas E Hagemeier; Fred Tudiver; Scott Brewster; Elizabeth J Hagy; Brittany Ratliff; Angela Hagaman; Robert P Pack Journal: Subst Abus Date: 2017-09-15 Impact factor: 3.716
Authors: Nicholas E Hagemeier; Fred Tudiver; Scott Brewster; Elizabeth J Hagy; Angela Hagaman; Robert P Pack Journal: Res Social Adm Pharm Date: 2015-12-29
Authors: Daniel M Hartung; Jennifer Hall; Sarah N Haverly; David Cameron; Lindsey Alley; Christi Hildebran; Nicole O'Kane; Deborah Cohen Journal: Pain Med Date: 2018-09-01 Impact factor: 3.750